Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ani Manichaikul, Jennifer N. Nguyen. Genetic studies as a tool for identifying novel potential targets for treatment of COPD. Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017

Member's Comments

No comment yet.

Related content which might interest you: Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate Source: Eur Respir J 2010; 35: 768-775 Year: 2010 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Using population insight studies to define effective prevention and identification interventions in COPD Source: Annual Congress 2011 - Quality of diagnosis and assessment in primary care Year: 2011 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019 Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Gene expression profiling: identifying novel gene targets for therapeutic intervention Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow Year: 2008 Novel strategy to identify genetic risk factors for COPD severity: genetically isolated populations Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD Year: 2008 N-ethyl-N-nitrosourea mutagenesis: a new tool for exploring lung disease Source: Annual Congress 2010 - Scientific Year in Review Year: 2010 Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia Year: 2004 A combinational approach to optimize biomarkers efficacy in identifying patients with sarcoidosis and monitoring respiratory functional worsening Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Population segmentation to identify priority targets for identification and behaviour change interventions in COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 A pooling based genome-wide analysis identifies new potential candidate genes for atopy in the echrs study Source: Annual Congress 2009 - Asthma genetics: from genome wide to single nucleotide polymorphisms Year: 2009 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity Source: Eur Respir J, 58 (4) 2100199; 10.1183/13993003.00199-2021 Year: 2021 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005